Blastocystosis is a gastrointestinal infection caused by the protozoan parasite Blastocystis hominis. This single-celled organism is commonly found in contaminated water and food, making it a prevalent cause of intestinal infections in humans. The clinical presentation of blastocystosis varies widely, with some individuals remaining asymptomatic while others experience symptoms such as abdominal pain, diarrhea, bloating, and nausea. The transmission of Blastocystis hominis occurs through the ingestion of cysts, which are the dormant and infective stage of the parasite. Risk factors for infection include poor sanitation, consumption of contaminated water or food, and close contact with infected individuals. Diagnosis of blastocystosis involves the identification of Blastocystis hominis cysts or trophozoites in stool samples. However, the interpretation of diagnostic results can be challenging due to the variable clinical significance of the parasite. In some cases, Blastocystis hominis is considered a commensal organism, while in others, it may contribute to gastrointestinal symptoms. Treatment options for symptomatic cases often involve antimicrobial agents, such as metronidazole or other antiprotozoal medications. However, controversies surround the interpretation of treatment efficacy, as some individuals may continue to harbor the parasite despite clinical resolution.
Title : Bioterrorism through the ages: Historical perspective, emerging threats, and medical countermeasures
Claudia Ferreira, Sorbonne University, France
Title : Changing population immunity to COVID-19 in the context of infection, vaccination, and emerging SARS-CoV-2 variants
Ranjan Ramasamy, ID-FISH Technology, United States
Title : From bench to preclinical evaluation: LL-37-derived peptides for combating orthopedic infections
Vincenzo Pennone, IRCCS Galeazzi Sant’Ambrogio Hospital, Italy
Title : Extensively drug-resistant bacterial infections: Confronting a global crisis with urgent solutions in prevention, surveillance, and treatment
Yazdan Mirzanejad, University of British Columbia, Canada
Title : Measles vaccination coverage indicators in 2023 and advance towards measles elimination and eradication by 2030
Pedro Plans Rubio, College of Physicians of Barcelona, Spain
Title : Personalized and precision medicine (PPM) as a unique healthcare model to se-cure the human healthcare, wellness and biosafety through the view of public health, network driven healthcare services and lifestyle management
Sergey Suchkov, N.D. Zelinskii Institute for Organic Chemistry of the Russian Academy of Sciences & InMedStar, Russian Federation